iifl-logo-icon 1

Astrazeneca Pharma India Ltd Share Price

7,190.6
(-2.73%)
Oct 22, 2024|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open7,421
  • Day's High7,421
  • 52 Wk High8,139
  • Prev. Close7,392.15
  • Day's Low7,170.2
  • 52 Wk Low 4,475
  • Turnover (lac)1,252.02
  • P/E137.08
  • Face Value2
  • Book Value280.05
  • EPS52.4
  • Mkt. Cap (Cr.)17,976.5
  • Div. Yield0.33
View All Historical Data
No Records Found

Astrazeneca Pharma India Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

7,421

Prev. Close

7,392.15

Turnover(Lac.)

1,252.02

Day's High

7,421

Day's Low

7,170.2

52 Week's High

8,139

52 Week's Low

4,475

Book Value

280.05

Face Value

2

Mkt Cap (₹ Cr.)

17,976.5

P/E

137.08

EPS

52.4

Divi. Yield

0.33

Astrazeneca Pharma India Ltd Corporate Action

16 Jul 2024

12:00 AM

AGM

Announcement Date: 16 Jul, 2024

arrow

27 May 2024

12:00 AM

Dividend

Dividend Amount: 24

Record Date: 05 Jul, 2024

arrow

24 Jul 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Astrazeneca Pharma India Ltd NEWS AND UPDATE

AstraZeneca Pharma Surges on CDSO Approval for Durvalumab in India
24 Sep 2024|06:20 PM

The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals.

Read More
AstraZeneca Pharma gets approval to launch cancer drug in India
24 Sep 2024|10:54 AM

The said indication is for the use of durvalumab in combination with chemotherapy as a neoadjuvant treatment.

Read More
Top 10 stocks for today - 24th September 2024
24 Sep 2024|09:00 AM

Here are some of the stocks that may see significant price movement today: Punjab National Bank, NTPC, Power Grid, etc.

Read More
Cancer Patients Benefit as GST on Medications Slashed
10 Sep 2024|12:22 PM

The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Astrazeneca Pharma India Ltd SHAREHOLDING SNAPSHOT

23 Oct, 2024|09:11 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 750.00%

Foreign: 75.00%

Indian: 0.00%

Non-Promoter- 7.99%

Institutions: 7.99%

Non-Institutions: 17.00%

Custodian: 0.00%

Share Price

Astrazeneca Pharma India Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

5

5

5

5

Preference Capital

0

0

0

0

Reserves

706.92

583.69

506.39

451.17

Net Worth

711.92

588.69

511.39

456.17

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

805.6

813.56

831.81

571

yoy growth (%)

-0.97

-2.19

45.67

5.01

Raw materials

-311.96

-294.95

-305.23

-181.09

As % of sales

38.72

36.25

36.69

31.71

Employee costs

-230.21

-219.54

-216.7

-153.53

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

83.04

127.09

113.97

43.8

Depreciation

-16.95

-20.13

-18.58

-14.74

Tax paid

-21.44

-33.79

-41.76

-17.89

Working capital

57.86

101.15

103.65

52.76

Other operating items

View Cash Flow
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

-0.97

-2.19

45.67

5.01

Op profit growth

-36.38

12.23

160.74

25.31

EBIT growth

-34.47

11.35

162.8

23.38

Net profit growth

-33.97

29.2

178.69

29.22

View Ratios

No Record Found

Astrazeneca Pharma India Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,887.55

162.644,52,670.53237.820.724,409.7498.75

Divis Laboratories Ltd

DIVISLAB

5,817.95

93.021,54,5124300.512,063507.93

Cipla Ltd

CIPLA

1,510.35

30.731,22,039.521,055.940.863,752.25346.39

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,339.65

75.141,12,925.714690.842,394201.77

Dr Reddys Laboratories Ltd

DRREDDY

6,662.4

26.981,11,144.221,417.20.65,823.91,458.55

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Astrazeneca Pharma India Ltd

Management

Register Office

Registrar Office

Chairman & Independent Directo

Narayan K Seshadri

Non-Exec. & Independent Dir.

Revathy Ashok

Non-Exec. & Independent Dir.

Shilpa Divekar Nirula

Managing Director

Sanjeev Panchal

Non Executive Director

Hooi Bien Chuah

Non Executive Director

Sylvia Lorena Varela Ramon

Executive Director

Bhavana Agrawal

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

AstraZeneca Pharma India (APIL) was incorporated on July 11, 1979. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company. The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology.AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Companys issued and paid up equity share capital. Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company. AstraZeneca Pharmaceuticals AB Sweden. AstraZeneca Pharma India Limited (the Company) is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC, United Kingdom.The company expanded the installed capacity of Injectables during the year 2001 by 0.20 crores (Nos) and with this expansion the total capacity has been increased to 2.40 crores (Nos).The Companys marketing activities including medical services have been certified for ISO 9002. During 2001-02 the company has commiss
Read More

Company FAQs

What is the Astrazeneca Pharma India Ltd share price today?

The Astrazeneca Pharma India Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹7190.6 today.

What is the Market Cap of Astrazeneca Pharma India Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Astrazeneca Pharma India Ltd is ₹17976.50 Cr. as of 22 Oct ‘24

What is the PE and PB ratio of Astrazeneca Pharma India Ltd?

The PE and PB ratios of Astrazeneca Pharma India Ltd is 137.08 and 25.22 as of 22 Oct ‘24

What is the 52 Week High and Low of Astrazeneca Pharma India Ltd?

The 52-week high/low is the highest and lowest price at which a Astrazeneca Pharma India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Astrazeneca Pharma India Ltd is ₹4475 and ₹8139 as of 22 Oct ‘24

What is the CAGR of Astrazeneca Pharma India Ltd?

Astrazeneca Pharma India Ltd's CAGR for 5 Years at 24.42%, 3 Years at 33.24%, 1 Year at 56.99%, 6 Month at 37.12%, 3 Month at 15.10% and 1 Month at 6.56%.

What is the shareholding pattern of Astrazeneca Pharma India Ltd?

The shareholding pattern of Astrazeneca Pharma India Ltd is as follows:
Promoters - 75.00 %
Institutions - 8.00 %
Public - 17.00 %

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp